Drugmaker Cipla Limited is set to acquire 100 per cent stake in Inzpera Healthsciences Limited, a subsidiary of Tata Industries, for an estimated Rs 110 crore. The acquisition will strengthen Cipla’s portfolio of products in the paediatric segment.

“Upon acquisition, Inzpera will become wholly-owned subsidiary of the company,” Cipla told the stock exchanges, indicating the exit of Tata Industries from the Mumbai-based company.

Working capital

“The enterprise value of Inzpera as on date is ₹120 crore. After accounting for necessary working capital adjustments, the purchase consideration has been determined to be about ₹110.65 crore for acquisition of equity shares and non-convertible redeemable preference shares, representing 100 per cent of Inzpera’s shareholding. The final consideratio

See Full Page